Abstract:ABSTRACT The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) mediates the receptor interaction and immune recognition and is considered a major target for vaccine design. However, its antigenic and immunogenic properties remain to be elucidated. In this study, we immunized mice with full-length S protein (FL-S) or its extracellular domain (EC-S) expressed by recombinant baculoviruses in insect cells. We found that the immunized mice developed high titers of anti-S antibodies with potent neutralizing activities against SARS pseudoviruses constructed with the S proteins of Tor2, GD03T13, and SZ3, the representative strains of 2002 to 2003 and 2003 to 2004 human SARS-CoV and palm civet SARS-CoV, respectively. These data suggest that the recombinant baculovirus-expressed S protein vaccines possess excellent immunogenicity, thereby inducing highly potent neutralizing responses against human and animal SARS-CoV variants. The antigenic structure of the S protein was characterized by a panel of 38 monoclonal antibodies (MAbs) isolated from the immunized mice. The epitopes of most anti-S MAbs (32 of 38) were localized within the S1 domain, and those of the remaining 6 MAbs were mapped to the S2 domain. Among the anti-S1 MAbs, 17 MAbs targeted the N-terminal region (amino acids [aa] 12 to 327), 9 MAbs recognized the receptor-binding domain (RBD; aa 318 to 510), and 6 MAbs reacted with the C-terminal region of S1 domain that contains the major immunodominant site (aa 528 to 635). Strikingly, all of the RBD-specific MAbs had potent neutralizing activity, 6 of which efficiently blocked the receptor binding, confirming that the RBD contains the main neutralizing epitopes and that blockage of the receptor association is the major mechanism of SARS-CoV neutralization. Five MAbs specific for the S1 N-terminal region exhibited moderate neutralizing activity, but none of the MAbs reacting with the S2 domain and the major immunodominant site in S1 showed neutralizing activity. All of the neutralizing MAbs recognize conformational epitopes. These data provide important information for understanding the antigenicity and immunogenicity of S protein and for designing SARS vaccines. This panel of anti-S MAbs can be used as tools for studying the structure and function of the SARS-CoV S protein.

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

SARS-CoV-2 Spike Protein Extrapolation for COVID Diagnosis and Vaccine Development

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens

The Spike Glycoprotein of Highly Pathogenic Human Coronaviruses: Structural Insights for Understanding Infection, Evolution and Inhibition.

The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development

Receptor-Binding Domains Of Spike Proteins Of Emerging Or Re-Emerging Viruses As Targets For Development Of Antiviral Vaccines

Recent Advance in the Research of SARS Coronavirus Spike Protein

MERS-CoV spike protein: Targets for vaccines and therapeutics

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants

Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development

Comprehensive Role of SARS‐CoV‐2 Spike Glycoprotein in Regulating Host Signaling Pathway

Vaccine design for severe acute respiratory syndrome coronavirus.

Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design

Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential.

A Single Dose SARS-CoV-2 Simulating Particle Vaccine Induces Potent Neutralizing Activities

Prospects for a MERS-CoV Spike Vaccine

Potential Therapeutic Approaches for the Early Entry of SARS-CoV-2 by Interrupting the Interaction Between the Spike Protein on SARS-CoV-2 and Angiotensin-Converting Enzyme 2 (ACE2)

Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects